Biopharma's New Drug for COPD Likely to be Approved
Source: Ram Selvaraju (04/22/2024)
Characteristics of the Buy-rated company's lead candidate make it "an intriguing commercial prospect," noted an H.C. Wainwright & Co. report.
read more >
PDUFA Date Coming Up for U.K. Biopharma
Source: Edward Nash (04/22/2024)
The company has a commercialization plan in place and is preparing further for approval, noted a Canaccord Genuity report.
read more >
Analyst Says Pharma Co. Has No True Competitor
Source: Andrew Tsai (04/19/2024)
Verona Pharma Plc. recently is gearing up for a potential FDA approval of its twice-daily ensifentrine, according to a Jefferies & Co. research note.
read more >
LA Biotech's Lower Revenue Will Be Short Lived
Source: Dr. Jonathan Aschoff (04/17/2024)
While Ontrak Inc. may have had a loss in revenue in 2023, this will be short-lived, according to a Roth MKM research note.
read more >
Chen in Q2 2024: It's Silver, Again, as Precious Metal Breaks Out
Source: Streetwise Reports (04/08/2024)
After being bullish on silver for at least the last year, asset manager Chen Lin feels a little vindicated by the precious metal's recent two-year high.
read more >